Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
661-680 of 847 trials

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNeurology

Myelofibrosis: Study of Pacritinib vs. Standard Treatment

We are investigating whether pacritinib can better reduce spleen size and improve symptoms in patients with myelofibrosis. This trial is for those with severe low platelet counts and compares pacritinib to physician's choice of therapy.

Post-Polycythaemia Vera MyelofibrosisPrimary MyelofibrosisPost-Essential Thrombocythaemia Myelofibrosis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Dystonia: Botulinum Toxin for Arm Tremors

We are exploring how different tests and imaging techniques can help determine the effectiveness of botulinum toxin for treating arm tremors in people with dystonia. This study aims to improve treatment options for those affected.

Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Oligometastatic Peritoneal Gastric Cancer: PIPAC Treatment Study

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard chemotherapy helps patients with oligometastatic peritoneal gastric cancer have better surgery outcomes and longer survival.

Metastatic Gastric Adenocarcinoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Nevoid Basal Cell Carcinoma Syndrome: Sonidegib Treatment Study

We are studying the effects of Sonidegib on patients with Nevoid Basal Cell Carcinoma Syndrome and sporadic basal cell carcinoma. The trial will assess treatment effectiveness, safety, and quality of life improvements.

Nevoid Basal Cell Carcinoma Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Crohn's Disease: Adalimumab Treatment Study

We are comparing a new approach using adalimumab for newly diagnosed Crohn's disease patients against standard treatments. The goal is to see which method is safer and more effective in the long run.

Crohn's Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Myelodysplastic Syndromes: Elritercept Treatment Study

We are testing elritercept to see if it can help reduce the need for blood transfusions in adults with certain types of myelodysplastic syndromes. The study will also look at how safe and tolerable the treatment is.

Myelodysplastic Syndrome (MDS)Anemia6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Multiple Myeloma: Belantamab Mafodotin vs. Daratumumab

We are studying a new treatment combination for people with newly diagnosed multiple myeloma who cannot have stem cell transplants. The goal is to see if it works better and is safer than the current standard treatment.

Multiple MyelomaConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib for patients with Chronic Myeloid Leukemia who have the T315I mutation and have not responded to ponatinib. The trial aims to see how well it works and how safe it is.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Kamada-AAT for Inhalation in Alpha-1 Antitrypsin Deficiency

We are studying a new inhalation treatment for adults with congenital Alpha-1 Antitrypsin Deficiency to see if it improves lung function compared to a placebo. The trial also looks at safety and immune responses to the treatment.

Congenital Alpha-1 Antitrypsin Deficiency>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Retinitis Pigmentosa: GS030 Gene Therapy Study

We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOphthalmology

High-Risk Polycythemia Vera: Ruxolitinib vs. Standard Therapy

We are comparing a new medication, ruxolitinib, with standard treatments for high-risk polycythemia vera patients. The goal is to see which option better prevents serious complications and improves quality of life.

Polycythemia Vera>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Advanced Breast Cancer: Inavolisib Treatment Study

We are studying a new treatment combining inavolisib with standard medications for patients with advanced hormone receptor-positive breast cancer. The goal is to see if this combination works better than a placebo in managing the disease.

Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Early Breast Cancer: Trastuzumab-Deruxtecan vs. Standard Care

We are studying a new treatment for early breast cancer patients who have had a molecular relapse. The trial aims to see if this new therapy clears cancer markers more effectively than standard treatments.

HER2-positive Breast CancerBreast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Psoriatic Arthritis: Sonelokimab Treatment Study

We are investigating whether sonelokimab can effectively reduce symptoms in adults with active psoriatic arthritis who have not yet tried biologic treatments. The study will also assess the safety of this new medication compared to a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Psoriatic Arthritis: Sonelokimab Study

We are investigating the effects of sonelokimab in adults with active psoriatic arthritis who haven't responded to other treatments. This study compares sonelokimab to a placebo and an existing medication to see how well it works.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

B-Cell Malignancies: BGB-16673 Treatment Study

We are investigating the safety and effectiveness of BGB-16673 combined with other treatments for patients with relapsed or refractory B-cell malignancies. This study aims to find the best dose and assess how well the treatment works.

Relapsed or Refractory B-Cell Malignancies>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Acute Demyelinating Syndromes in Children: Azathioprine vs. Rituximab

We are studying whether starting treatment immediately with azathioprine or rituximab helps children with anti-MOG antibodies better than delaying treatment until a second attack. The goal is to see which method reduces relapses and improves health outcomes.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Hereditary Angioedema: Deucrictibant Tablet Study

We are evaluating a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The study aims to determine its effectiveness and safety compared to a placebo.

Hereditary Angioedema3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine